REG - Ergomed plc - Notice of Preliminary Results: Date Change

ErgomedAnnouncement

20/03/2018 07:05

RNS Number : 2051I
Ergomed plc
20 March 2018
 

PRESS RELEASE
 
Notice of Preliminary Results: Date Change
 
 
London, UK - 20 March 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, announces that the Company will publish its Preliminary Results for the year ending 31 December 2017 on 11 April 2018.
 
Stephen Stamp, Chief Executive Officer, will host a presentation and conference call for analysts at 9:30am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.
 
- ENDS -
 
Enquiries:
 




Ergomed plc


Tel: +44 (0) 1483 503205




Stephen Stamp (Chief Executive Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)








James Black (Joint Broker)


















N+1 Singer


Tel: +44 (0) 20 7496 3000




Alex Price (Joint Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Philippa Gardner


ergomed@consilium-comms.com














MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke













 
 
About Ergomed
 
Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORSFSFWUFASEDD